Given that EPHA2 is one of the key regulators of cell proliferation, migration, invasion and metastatic spread, targeting this RTK in several types of cancers including breast [59], CRC [24, 26, 60, 61], lung [44], brain [62] and prostate [63] impairs tumor growth and metastasis. This evidence concerns the gene EPHA2 and cancer.